Alder BioPharmaceuticals Reports Second Quarter 2015 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Leerink Partners Raises Price Target on Alder BioPharma (ALDR) to $62 Following 2Q15
August 6, 2015 10:03 AM EDTLeerink Partners reiterated an Outperform rating on Alder Biopharm (NASDAQ: ALDR), and raised the price target to $62.00 (from $40.00), following 2Q15 results. ALDR reported 2Q15 EPS of $(0.46) that was below consensus estimates of $(0.40).
Analyst Joseph Schwartz commented, "On Wednesday (8/5) after the close, ALDR... More
Alder BioPharma (ALDR) Misses Q2 EPS by 6c
August 5, 2015 4:23 PM EDTAlder BioPharma (NASDAQ: ALDR) reported Q2 EPS of ($0.46), $0.06 worse than the analyst estimate of ($0.40).
For earnings history and earnings-related data on Alder BioPharma (ALDR) click here.
... More